A systematic review on efficiency of microneme proteins to induce protective immunity against Toxoplasma gondii
- 331 Downloads
Toxoplasma gondii is an intracellular parasite infecting almost all warm-blooded animals. Many studies on vaccination have been performed previously, and micronemal proteins (MICs) have crucial importance in this regard. The current review aims to reveal the efficiency of MICs as target antigen, adjuvants, animal models (species/strain), T. gondii strains for challenge infection, and routes of vaccine to prevent Toxoplasma infection. A comprehensive literature search was performed on April 18, 2018, in several known databases. Studies were included when evaluating vaccines based on MIC against T. gondii compared to that of a control group. Two independent researchers done the search process, study choice, and data extraction. A total of 28 articles published were selected for further analysis. Among them, 57.03% of the studies focused on MIC3 and its epitopes. SAG1 was further used in cocktail vaccines compared to other antigens. GM-CSF and Freund’s complete were the predominant adjuvants used. BALB/c mice have been introduced as a proper model for lethal challenge. Virulent T. gondii (RH) was utilized more than other strains for challenge. Among MICs, the results of vaccination with MIC1-4, MIC6, and PLP1 demonstrated significantly strong humoral and cellular immunity, increased survival time, and reduced cyst burden in the mice. This review summarizes the latest results on MIC-based vaccines and presents that the most effective vaccination procedure is the administration of the cocktail vaccines. Our survey can serve as a basis for further studies to develop more efficient novel vaccines against T. gondii for animals and humans.
KeywordsDNA vaccine Microneme proteins Recombinant vaccine Toxoplasmosis Vaccine candidates
The authors would like to acknowledge Miss Tooran Nayeri and Miss Zahra Hosseini Nejad for their kind collaboration and the Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran, for their support to this study. This study was financially supported by the Vice-Chancellor of Mazandaran University of Medical Sciences (Project Number: 10221).
Compliance with ethical standards
Declaration of interests
The authors report that they have no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
- 9.Montazeri M, Sharif M, Sarvi S, Mehrzadi S, Ahmadpour E, Daryani A (2017) A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006–2016). Front Microbiol 8Google Scholar
- 13.Pinzan CF, Sardinha-Silva A, Almeida F, Lai L, Lopes CD, Lourenço EV, Panunto-Castelo A, Matthews S, Roque-Barreira MC (2015) Vaccination with recombinant microneme proteins confers protection against experimental toxoplasmosis in mice. PLoS One 10(11):e0143087PubMedPubMedCentralCrossRefGoogle Scholar
- 14.Macêdo Junior AG, Cunha Junior JP, Cardoso THS, Silva MV, M Santiago F, Silva JS, Pirovani CP, Silva DAO, Mineo JR, Mineo TWP (2013) SAG2A protein from Toxoplasma gondii interacts with both innate and adaptive immune compartments of infected hosts. Parasit Vectors 6:163Google Scholar
- 23.Beghetto E, Nielsen HV, Del Porto P, Buffolano W, Guglietta S, Felici F, Petersen E, Gargano N (2005) A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts. J Infect Dis 191(4):637–645PubMedCrossRefGoogle Scholar
- 25.Rosenberg C, De Craeye S, Jongert E, Gargano N, Beghetto E, Del Porto P, Vorup-Jensen T, Petersen E (2009) Induction of partial protection against infection with Toxoplasma gondii genotype II by DNA vaccination with recombinant chimeric tachyzoite antigens. Vaccine 27(18):2489–2498PubMedCrossRefGoogle Scholar
- 29.Ismael AB, Hedhli D, Cérède O, Lebrun M, Dimier-Poisson I, Mévélec M-N (2009) Further analysis of protection induced by the MIC3 DNA vaccine against T. gondii: CD4 and CD8 T cells are the major effectors of the MIC3 DNA vaccine-induced protection, both lectin-like and EGF-like domains of MIC3 conferred protection. Vaccine 27(22):2959–2966PubMedCrossRefGoogle Scholar
- 33.Ghaffarifar F, Naserifar R, Jafari Madrak M (2014) Eukaryotic plasmids with Toxoplasma gondii dense granule antigen (GRA 5) and microneme 3 (MIC3) genes as a cocktail DNA vaccine and evaluation of immune responses in BALB/C mice. J Clin Med Genom 3 (121):2Google Scholar
- 38.Yan H-K, Yuan Z-G, Song H-Q, Petersen E, Zhou Y, Ren D, Zhou D-H, Li H-X, Lin R-Q, Yang G-L (2012) Vaccination with a DNA vaccine coding perforin-like protein 1 (TgPLP1) and MIC6 induces significant protective immunity against Toxoplasma gondii. Clin Vaccine Immunol:CVI. 05578–05511Google Scholar
- 41.Yao Y, He S, Wang H, Zhou H, Zhao H, Li T, Xue M, Zhu X (2010) Protective immunity induced in mice by multiantigenic DNA vaccine with genes encoding SAG1 and MIC8 of Toxoplasma gondii. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese Journal of Parasitology & Parasitic Diseases 28(2):81–88Google Scholar
- 42.Zhao H, Huang F, Guo J, Tan G (2013) Evaluation on the immune response induced by DNA vaccine encoding MIC8 co-immunized with IL-12 genetic adjuvant against Toxoplasma gondii infection. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese Journal of Parasitology & Parasitic Diseases 31(4):284–289Google Scholar
- 61.Boyle JP, Rajasekar B, Saeij JP, Ajioka JW, Berriman M, Paulsen I, Roos DS, Sibley LD, White MW, Boothroyd JC (2006) Just one cross appears capable of dramatically altering the population biology of a eukaryotic pathogen like Toxoplasma gondii. Proc Natl Acad Sci 103(27):10514–10519PubMedCrossRefGoogle Scholar
- 62.Carneiro ACAV, Andrade GMQ, Costa JGL, Pinheiro BV, Vasconcelos-Santos DV, Ferreira AM, Su C, Januario JN, Vitor RWA (2013) Genetic characterization of Toxoplasma gondii revealed highly diverse genotypes for isolates from newborns with congenital toxoplasmosis in southeastern Brazil. J Clin Microbiol 51(3):901–907PubMedPubMedCentralCrossRefGoogle Scholar
- 65.Mordue DG, Hunter CA Innate immunity toToxoplasma gondii—chapter 24Google Scholar